FN1 and asthma: Increased anti-fibrotic effect of 1,25D3 was observed in BSMCs from asthma (Figures 5A, C and Table S1A; FN1 average fold-decrease 6.78 ± 0.65, p < 0.001; COL1A1 average fold-decrease 3.68 ± 1.21, p < 0.05 p = 0.014) compared to BSMCs from COPD (Figures 5B, D and Table S1A).